Impact BioMedical, Inc. (IBO) Year-over-year earnings per share growth for the last twelve months
Impact BioMedical Inc is implementing automated screening to accelerate drug time-to-market, which impacts quarterly EPS growth rates. The application of AI in biodata analysis optimizes preclinical stages, and the current level is approximately 95.20. The holding's success now depends on patent protection and asset licensing, which stabilizes investor confidence in earnings per share dynamics.
Analytical breakdowns for Impact BioMedical, Inc. (IBO)
- share price and expert price forecast:
- market capitalization details:
- book capitalization data:
- business debt structure and liquidity details:
Debt to Equity Impact BioMedical Inc|IBO - Long-Term Liabilities to Equity|Short-Term Debt to Capital Impact BioMedical Inc|IBO - Company Aggregate Debts|Debts to Book Capitalization Impact BioMedical|IBO - Company Long-Term Liabilities|Company Current Liabilities Impact BioMedical|Quick Liquidity Indicator impactbiomedinc.com
- earnings and valuation multiples indicators:
IBO - Final Profit|Projected Future Earnings Impact BioMedical Inc|IBO - Price to Earnings Ratio|Forward P/E Multiple Impact BioMedical|IBO - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Impact BioMedical|IBO - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Impact BioMedical|IBO - Net earnings per share for the last 12 months|Quarterly EPS earnings growth impactbiomedinc.com|IBO - Earnings per share growth rate in current year|Earnings growth forecast for next year Impact BioMedical Inc
Initial company analysis:Impact BioMedical - IBO
The specificity of Impact BioMedical Inc (IBO) lies in the prolonged development cycles of proprietary therapies, which necessitates strict control over investment efficiency. This indicator measures the rate of change in net earnings per share, allowing for the identification of a gap between operating revenue and actual yield, which, through a cross-section of quarterly EPS dynamics, helps determine the risk of asset overvaluation.
Main competitors
HLN: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Kenvue Inc (KVUE)|Year-over-year earnings per share growth for the last twelve months Verona Pharma Corp|MENS: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth LGND|Year-over-year net earnings per share change for the last twelve months amneal.com|Year-over-year earnings per share growth for the last twelve months Perrigo PRGO|ALVO - Year-over-year net earnings per share growth for the last 12 months|LQDA - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share trend for the last twelve months GLPG|ANIP: Quarterly EPS earnings growth|mannkindcorp.com (MNKD) - Quarterly EPS earnings growth|AMPH (Amphastar Pharmaceuticals, Inc.) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Pacira Pharmaceuticals (PCRX)|Year-over-year net earnings per share growth for the last 12 months SPRY (ARS Pharma)|Year-over-year earnings per share growth rate for the last twelve months TBPH|Aquestive Therapeutics - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months SCPH|Tectonic - Quarterly EPS earnings growth|TNXP: Year-over-year earnings per share growth for the last twelve months|SXTC: Quarterly EPS earnings growth|EPRX - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months BioHarvest Sciences|Earnings per share growth in annualized terms for the last twelve months invizyne.com EXOZ|Year-over-year earnings per share growth for the last twelve months Oramed Pharmaceuticals (ORMP)|Year-over-year net earnings per share growth for the last 12 months enterabio.com ENTX|Quarterly EPS earnings growth HYFT (MindWalk)|ABVC BioPharma, Inc (ABVC) - Earnings per share growth in annualized terms for the last twelve months|Cumberland Pharmaceuticals - Quarterly EPS earnings growth|QNTM (quantumbiopharma.com) - Year-over-year earnings per share growth for the last 12 months|FGEN: Quarterly EPS earnings growth|TELO - Year-over-year net earnings per share change for the last twelve months|RANI (Rani Therapeutics Holdings) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Synergy CHC Corporation (SNYR)|Quarterly EPS earnings growth RLYB|Quarterly EPS earnings growth lexariabioscience.com (LEXX)|Year-over-year earnings per share growth for the last twelve months Pulmatrix PULM|Pheton Holdings Limited - Year-over-year earnings per share growth for the last twelve months|APM: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months LYRA (Lyra Therapeutics Inc)|TNFA: Quarterly EPS earnings growth|YCBD - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months PainReform|Year-over-year earnings per share growth for the last 12 months CYTO (Auris Medical)|Quarterly EPS earnings growth LIPO|Year-over-year net earnings per share growth for the last 12 months OptiNose Corp OPTN|Quarterly EPS earnings growth PIRS (Pieris Pharmaceuticals)|Year-over-year net earnings per share change for the last twelve months procapsgroup.com (PROC)|Petros Pharmaceuticals, Inc. - Quarterly EPS earnings growth|QLI: Year-over-year earnings per share growth for the last twelve months|ACELYRIN, Inc. (SLRN) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months TFF Pharmaceuticals, Inc (TFFP)
